Therefore, we sought to review the literature to better understand the risk factors associated with the prevalence of anaemia in patients with CKD treated according to standard of care and to quantify the associations between anaemia (or Hb concentration) and the risks of patient mortality, hospitalisation, major adverse cardiac events (MACE), or CKD progression. This evidence concerns the gene GSTM1 and anemia (phenotype).